TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05457205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical neuromodulation
Description: Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical neuromodulation
Description: Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical neuromodulation
Description: Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical neuromodulation
Description: Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.
Study: NCT06572150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation - Minimal Electrophysiology
Description: Participants will undergo standard work-up and follow-up for DBS, but with minimal intraoperative electrophysiological testing.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep Brain Stimulation - Standard
Description: Participants underwent DBS surgery with standard intraoperative electrophysiological testing.
Study: NCT06111742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside Entertainment and Relaxation Theater (BERT)
Description: BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
Study: NCT06455280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
Study: NCT05013736

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: 3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.

Intervention type: BEHAVIORAL
Intervention: Behavioral Assessments
Description: The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.

Intervention type: DEVICE
Intervention: Non invasive Transcranial Magnetic Stimulation
Description: TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
Study: NCT05402020

Intervention type: DRUG
Intervention: Tiotropium (Tio)
Description: Tiotropium (Tio)

Intervention type: DRUG
Intervention: Inhaled corticosteroids (ICS)
Description: Inhaled corticosteroids (ICS)

Intervention type: DRUG
Intervention: Olodaterol (Olo)
Description: Olodaterol (Olo)

Intervention type: DRUG
Intervention: Long-acting β2-agonists (LABA)
Description: Long-acting β2-agonists (LABA)
Study: NCT06463678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIEW-1201
Description: Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NATACYN®
Description: Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
Study: NCT06439004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Performing QST on the dominant hand, right forearm, right flank and lower back.
Study: NCT06271174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbocaine
Description: After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Profofol and/or Suxaméthonium and/or Sévoflurane
Description: General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Profofol and/or Suxaméthonium and/or Sévoflurane
Description: General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics.
Study: NCT06483074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: empagliflozin oral 10mg daily for 6 months
Study: NCT05825261

Intervention type: OTHER
Intervention: voice sampling
Description: Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated

Intervention type: OTHER
Intervention: capnometry
Description: Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
Study: NCT06008834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First-day discharge protocol
Description: Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
Study: NCT04976036

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
Study: NCT05344885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPT-Standard
Description: The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q\&A section that contains frequently asked questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPT-Enhanced
Description: DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
Study: NCT06319352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active UroShield
Description: Participants will have an active device (i.e., ultrasound energy is being produced by actuator) attached to their urinary catheter tube.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UroShield
Description: Participants will have an inactive device (i.e., no ultrasound energy being produced by the actuator) attached to their urinary catheter tube. All other aspects of the sham device (look, weight, feel, sound, and operation) are identical to the active device.
Study: NCT06405620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistance robot
Description: the child controls the robot at his parent's home from his room
Study: NCT05439642

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of health related quality of life
Description: Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
Study: NCT05947578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLZ-2002
Description: Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)
Study: NCT06259227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) training
Description: The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
Study: NCT05882292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401
Description: ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
Study: NCT06008626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosa Procedure
Description: Cryotherapy
Study: NCT06628687

Intervention type: DRUG
Intervention: Omaveloxolone
Description: Administered as specified in the treatment arm.
Study: NCT05093933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: 2.5, 5.0, or 10.0 mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
Study: NCT05291689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Study: NCT05973214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT for IEI

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: CBT for IEI
Study: NCT05169957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 24-45 Gy delivered in three fractions to up to 4 liver metastases
Study: NCT04627662

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tele-STELLA
Description: Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
Study: NCT06575452

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood, urine and tumoral tissue samples
Description: Blood, urine and tumoral tissue samples
Study: NCT06575452

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tumoral tissue samples
Description: tumoral tissue samples

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tumoral tissue samples
Description: tumoral tissue samples
Study: NCT05533697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4359
Description: Intramuscular Injection
Study: NCT05250180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: treatment as usual as dictated by their treatment team
Study: NCT06501183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CDH17 CAR-T cells
Description: Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
Study: NCT04854499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study: NCT05325437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and azygoportal disconnection
Description: The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
Study: NCT06371508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education based on breast cancer and breast examination
Description: Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
Study: NCT06120504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35T
Description: Given into the vein (IV; intravenously)
Study: NCT05533697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4359
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-4359
Description: Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT04991103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaraVRD
Description: All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22).
Study: NCT04620759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
Study: NCT04418232

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Alianza Latina
Description: The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
Study: NCT04854499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously
Study: NCT05674552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exogenous ketone ester
Description: 500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
Study: NCT04414514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream
Description: Topical Ruxolitinib 1.5% Cream
Study: NCT04605055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
Study: NCT06515184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Description: Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PharmaNord Placebo
Description: Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Description: Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.
Study: NCT04712565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech Implant System Profile EV
Description: dental implant with a sloped neck configuration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astra Tech Implant System EV
Description: dental implant with a conventional neck configuration